Markets
MarketMind AI
Baskets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
All Features
Widgets
More
Search Stock, IPO, MF
Open in App
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
Financials
Charts & Report
Charts and Graphs
Stock Report Pdf
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Price History/Seasonality
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
IPO
Alerts
(1)
About
Alivus Life Sciences Ltd.
NSE: ALIVUS
|
BSE: 543322
|
ISIN: INE03Q201024
|
Industry: Pharmaceuticals
|
Strong Performer, Getting Expensive
1370.6000
22.80
(
1.69
%)
NSE
Sep 16, 2026
15:31 PM
67.35% Gain from 52W Low
Volume:
153.2K
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Alivus Life Sciences Ltd.
16 Jul 2024, 12:00AM
1370.60
1.69%
Glenmark Life Sciences Ltd
Buy:
Alivus Life Sciences Ltd.
by
Hem Securities
Target: 987
Hem Securities
Alivus Life Sciences Ltd. is trading
above its 200 day SMA
of 1055.3
More from Alivus Life Sciences Ltd.
Recommended
Better than Apple: The best NSE IPO trades happened before most of us had demat accounts
|
16 Sep 2026, 07:35PM
Market closes higher, led by gains in FMCG and PSU banking stocks
Trendlyne Marketwatch |
16 Sep 2026, 03:58PM
Glenmark Life Sciences: The hived off API business of Glenmark Pharma goes public
|
27 Jul 2021